Summary of Key Points Core Viewpoint - Heptares Therapeutics has been actively repurchasing its shares, indicating a commitment to enhancing shareholder value through buybacks, which may reflect confidence in its future prospects [2]. Buyback Details - On December 30, Heptares Therapeutics repurchased 300,000 shares at prices ranging from HKD 11.920 to HKD 12.210, totaling HKD 3.6305 million [2]. - The stock closed at HKD 12.160 on the same day, marking a decline of 1.30% with a total trading volume of HKD 54.2048 million [2]. - Year-to-date, the company has conducted 69 buybacks, acquiring a total of 25.743 million shares for a cumulative amount of HKD 194 million [2]. Historical Buyback Data - The buyback history includes various transactions with the highest repurchase price recorded at HKD 15.330 and the lowest at HKD 2.270 [3][4]. - Notable buyback transactions include: - December 15: 400,000 shares at a maximum price of HKD 13.000, totaling HKD 5.0712 million [2]. - June 17: 110,000 shares at a maximum price of HKD 8.320, totaling HKD 8.6288 million [3]. - February 7: 239,800 shares at a maximum price of HKD 4.130, totaling HKD 9.5333 million [4].
和铂医药-B(02142.HK)12月30日回购363.05万港元，年内累计回购1.94亿港元